Intuitive Surgical, Inc. has celebrated significant achievements in the fourth quarter of 2025, including $2.87 billion in revenue and robust earnings per share of $2.53, exceeding expectations for the twelfth consecutive quarter. The recent FDA approvals for the da Vinci 5 system in cardiac procedures and the formation of a specialized cardiac team are key strategic moves aimed at enhancing future growth, despite a 9.1% decline in share price over the past month. With year-over-year revenue growth at 18.8%, analysts remain divided on the stock's valuation, amidst a market capitalization of approximately $187.84 billion.
“David Gardner · has positions in · Amazon, Duolingo, Etsy, and Intuitive Surgical”
“The Motley Fool · has positions in and recommends · Amazon, Duolingo, Etsy, International Business Machines, Intuitive Surgical, and eBay”
“Intuitive Surgical · announced · FDA 510(k) clearance · for the da Vinci 5 system to be used in certain cardiac procedures”
“Intuitive Surgical · expects · limited number of United States centers · to collaborate through 2026 to establish initial da Vinci 5 cardiac programs”
“Intuitive Surgical · received · FDA clearance · to expand the use of the da Vinci Single Port (SP) robotic system for inguinal hernia repair, cholecystectomy and appendectomy surgeries”
“Intuitive Surgical · carries · Zacks Rank · #3 (Hold)”
“Intuitive Surgical Inc. · was initiated with a · Buy rating · and a $660 target price at TD Cowen”
“Intuitive Surgical · faced · significant issues · last year”
“Intuitive Surgical · recently fell · shares · as the market was unimpressed with its latest quarterly update”
“Intuitive Surgical · is focused on · surgical robotics · 100%”
“Intuitive Surgical · installed · da Vinci surgical robots · 1,721”
“Intuitive Surgical · ended · 2025 on a strong note”
